Cinclus Pharma Holding AB (publ)
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in … Read more
Cinclus Pharma Holding AB (publ) (J8P) - Total Liabilities
Latest total liabilities as of September 2025: €157.99 Million EUR
Based on the latest financial reports, Cinclus Pharma Holding AB (publ) (J8P) has total liabilities worth €157.99 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cinclus Pharma Holding AB (publ) - Total Liabilities Trend (2021–2024)
This chart illustrates how Cinclus Pharma Holding AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cinclus Pharma Holding AB (publ) Competitors by Total Liabilities
The table below lists competitors of Cinclus Pharma Holding AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thor Medical ASA
OL:TRMED
|
Norway | Nkr87.50 Million |
|
Ilshinstone
KO:007110
|
Korea | ₩34.89 Billion |
|
Hwa Sung Ind
KO:002460
|
Korea | ₩325.72 Billion |
|
AGTech Holdings Limited
PINK:AGTEF
|
USA | $6.59 Billion |
|
MAYO Human Capital Inc.
TWO:6738
|
Taiwan | NT$172.79 Million |
|
Gevelot
PA:ALGEV
|
France | €54.03 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Cinclus Pharma Holding AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cinclus Pharma Holding AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cinclus Pharma Holding AB (publ) (2021–2024)
The table below shows the annual total liabilities of Cinclus Pharma Holding AB (publ) from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €45.68 Million | -73.32% |
| 2023-12-31 | €171.21 Million | +190.70% |
| 2022-12-31 | €58.90 Million | +193.36% |
| 2021-12-31 | €20.08 Million | -- |